The only curative treatment option for hepatocellular carcinoma patients is either a surgical resection or liver transplantation. Due to limited supply of donor organs and the stringent selection criteria for liver transplantation, resection is the mainstay of therapy, particularly for patients with preserved liver function and small tumors with no portal hypertension. However, tumor recurrences and subsequent death is common after resection, which has prompted a search for an effective adjuvant therapy to improve patient outcomes. Studies have looked at various adjuvant treatment modalities, including systemic chemotherapy, intra-arterial approaches with or without chemotherapy, and the use of cytokines, but there is still no established role for adjuvant therapy after a curative liver resection. Unfortunately, many of these trials lack adequate sample sizes, and are heterogeneous in the patient populations and study end points, thereby limiting robust conclusions. Based on current available data, the role of adjuvant therapy after liver resection needs to be further investigated. The use of molecular targeted therapy focusing on the vascular endothelial growth factor pathway appears to be a promising step. Clinical trials assessing adjuvant therapies after a curative liver resection are urgently needed. These should ideally be prospective, randomized trials with properly selected patients and appropriate end points.

Keywords:
Adjuvant therapy, Hepatocellular carcinoma, Curative resection
1.
Parkin DM, Bray F, Ferlay J, Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153–156.
2.
Samuel M, Chow PK, Chan Shih-Yen E, Machin D, Soo KC: Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev 2009;1:CD001199.
3.
Cherqui D: Role of adjuvant treatment in liver transplantation for advanced hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 1998;5:35–40.
4.
Altekruse SF, McGlynn KA, Reichman ME: Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27:1485–1491.
5.
El-Serag HB, Marrero JA, Rudolph L, Reddy KR: Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008;134:1752–1763.
6.
Lai EC, Fan ST, Lo CM, Chu KM, Liu CL, Wong J: Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Ann Surg 1995;221:291–298.
7.
Llovet JM, Bruix J, Gores GJ: Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy. Hepatology 2000;31:1019–1021.
8.
Mazzaferro V, Regalia E, Doci R, et al: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693–699.
9.
Shetty K, Timmins K, Brensinger C, et al: Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl 2004;10:911–918.
10.
Bismuth H, Houssin D, Ornowski J, Meriggi F: Liver resections in cirrhotic patients: a Western experience. World J Surg 1986;10:311–317.
11.
Fan ST, Lo CM, Liu CL, et al: Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg 1999;229:322–330.
12.
Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A: Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 1993;218:145–151.
13.
Farmer DG, Rosove MH, Shaked A, Busuttil RW: Current treatment modalities for hepatocellular carcinoma. Ann Surg 1994;219:236–247.
14.
Chen MF, Hwang TL, Jeng LB, Jan YY, Wang CS, Chou FF: Hepatic resection in 120 patients with hepatocellular carcinoma. Arch Surg 1989;124:1025–1028.
15.
Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J: Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000;89:500–507.
16.
Mazzaferro V, Romito R, Schiavo M, et al: Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006;44:1543–1554.
17.
el-Assal ON, Yamanoi A, Soda Y, Yamaguchi M, Yu L, Nagasue N: Proposal of invasiveness score to predict recurrence and survival after curative hepatic resection for hepatocellular carcinoma. Surgery 1997;122:571–577.
18.
Kubo S, Hirohashi K, Tanaka H, et al: Effect of viral status on recurrence after liver resection for patients with hepatitis B virus-related hepatocellular carcinoma. Cancer 2000;88:1016–1024.
19.
Wu CC, Ho WL, Chen JT, Tang JS, Yeh DC, P’eng FK: Hepatitis viral status in patients undergoing liver resection for hepatocellular carcinoma. Br J Surg 1999;86:1391–1396.
20.
Hanazaki K, Wakabayashi M, Sodeyama H, Kajikawa S, Amano J: Hepatic function immediately after hepatectomy as a significant risk factor for early recurrence in hepatocellular carcinoma. Hepatogastroenterology 1999;46:3201–3207.
21.
Tangkijvanich P, Anukulkarnkusol N, Suwangool P, et al: Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol 2000;31:302–308.
22.
Yamamoto M, Arii S, Sugahara K, Tobe T: Adjuvant oral chemotherapy to prevent recurrence after curative resection for hepatocellular carcinoma. Br J Surg 1996;83:336–340.
23.
Ono T, Nagasue N, Kohno H, et al: Adjuvant chemotherapy with epirubicin and carmofur after radical resection of hepatocellular carcinoma: a prospective randomized study. Semin Oncol 1997;24(2 Suppl 6):S6-18–S6-25.
24.
Hasegawa K, Takayama T, Ijichi M, et al: Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial. Hepatology 2006;44:891–895.
25.
Davis AJ, Tannock JF: Repopulation of tumour cells between cycles of chemotherapy: a neglected factor. Lancet Oncol 2000;1:86–93.
26.
Ono T, Yamanoi A, Nazmy El Assal O, Kohno H, Nagasue N: Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials. Cancer 2001;91:2378–2385.
27.
Lau WY, Lai EC, Leung TW, Yu SC: Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival. Ann Surg 2008;247:43–48.
28.
Lau WY, Leung TW, Ho SK, et al: Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 1999;353:797–801.
29.
Partensky C, Sassolas G, Henry L, Paliard P, Maddern GJ: Intra-arterial iodine 131-labeled lipiodol as adjuvant therapy after curative liver resection for hepatocellular carcinoma: a phase 2 clinical study. Arch Surg 2000;135:1298–1300.
30.
Boucher E, Corbinais S, Rolland Y, et al: Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma. Hepatology 2003;38:1237–1241.
31.
Tabone M, Vigano’ L, Ferrero A, Pellerito R, Carbonatto P, Capussotti L: Prevention of intrahepatic recurrence by adjuvant (131)iodine-labeled lipiodol after resection for hepatocellular carcinoma in HCV-related cirrhosis. Eur J Surg Oncol 2007;33:61–66.
32.
Ren ZG, Lin ZY, Xia JL, et al: Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor: a retrospective control study. World J Gastroenterol 2004;10:2791–2794.
33.
Fan J, Zhou J, Wu ZQ, et al: Efficacy of different treatment strategies for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol 2005;11:1215–1219.
34.
Zhong C, Guo RP, Li JQ, et al: A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for stage III A hepatocellular carcinoma. J Cancer Res Clin Oncol 2009;135:1437–1445.
35.
Lai EC, Lo CM, Fan ST, Liu CL, Wong J: Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial. Arch Surg 1998;133:183–188.
36.
Castells A, Bruix J, Ayuso C, et al: Transarterial embolization for hepatocellular carcinoma. Antibiotic prophylaxis and clinical meaning of postembolization fever. J Hepatol 1995;22:410–415.
37.
Chung JW, Park JH, Han JK, et al: Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology 1996;198:33–40.
38.
Georgiades CS, Hong K, D’Angelo M, Geschwind JF: Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2005;16:1653–1659.
39.
Baron S, Tyring SK, Fleischmann WR Jr, et al: The interferons. Mechanisms of action and clinical applications. JAMA 1991;266:1375–1383.
40.
Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler IJ: Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA 1995;92:4562–4566.
41.
Ikeda K, Saitoh S, Suzuki Y, et al: Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study. Cancer 1998;82:827–835.
42.
Yoshida H, Shiratori Y, Moriyama M, et al: Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999;131:174–181.
43.
Lai CL, Wu PC, Lok AS, et al: Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial. Br J Cancer 1989;60:928–933.
44.
Lo CM, Liu CL, Chan SC, et al: a randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 2007;245:831–842.
45.
Sun HC, Tang ZY, Wang L, et al: Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol 2006;132:458–465.
46.
Ikeda K, Arase Y, Saitoh S, et al: Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor – a prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000;32:228–232.
47.
Kubo S, Nishiguchi S, Hirohashi K, et al: Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 2001;134:963–967.
48.
Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H: Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg 2002;89:418–422.
49.
Breitenstein S, Dimitroulis D, Petrowsky H, Puhan MA, Mullhaupt B, Clavien PA: Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg 2009;96:975–981.
50.
Rosenberg SA, Yannelli JR, Yang JC, et al: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994;86:1159–1166.
51.
Takayama T, Sekine T, Makuuchi M, et al: Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000;356:802–807.
52.
Moriwaki H, Muto Y, Ninomiya M, Kawai K, Suzuki Y, Seto T: Inhibitory effects of synthetic acidic retinoid and polyprenoic acid on the development of hepatoma in rats induced by 3′-methyl-N, N-dimethyl-4-aminoazobenzene. Gastroenterol Jpn 1988;23:546–552.
53.
Muto Y, Moriwaki H, Ninomiya M, et al: Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 1996;334:1561–1567.
54.
Muto Y, Moriwaki H, Saito A: Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med 1999;340:1046–1047.
55.
Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M, Kojiro M: Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 1998;28:68–77.
56.
Thomas MB, Abbruzzese JL: Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol 2005;23:8093–8108.
57.
Ferro V, Dredge K, Liu L, et al: PI-88 and novel heparan sulfate mimetics inhibit angiogenesis. Semin Thromb Hemost 2007;33:557–568.
58.
Liu CJ, Lee PH, Lin DY, et al: Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. J Hepatol 2009;50:850–853.
59.
Chang YS, Adnane J, Trail PA, et al: Sorafenib (BAY 43–9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 2007;59:561–574.
60.
Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–390.
61.
Del Pozo AC, Lopez P: Management of hepatocellular carcinoma. Clin Liver Dis 2007;11:305–321.
62.
Llovet JM, Schwartz M, Mazzaferro V: Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005;25:181–200.
63.
Chan ES, Chow PK, Tai B, Machin D, Soo K: Neoadjuvant and adjuvant therapy for operable hepatocellular carcinoma. Cochrane Database Syst Rev 2000;2:CD001199.
64.
Schwartz JD, Schwartz M, Mandeli J, Sung M: Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol 2002;3:593–603.
65.
Nagasue N, Kohno H, Chang YC, et al: Liver resection for hepatocellular carcinoma. Results of 229 consecutive patients during 11 years. Ann Surg 1993;217:375–384.
66.
Izumi R, Shimizu K, Iyobe T, et al: Postoperative adjuvant hepatic arterial infusion of lipiodol containing anticancer drugs in patients with hepatocellular carcinoma. Hepatology 1994;20:295–301.
67.
Kohno H, Nagasue N, Hayashi T, et al: Postoperative adjuvant chemotherapy after radical hepatic resection for hepatocellular carcinoma (HCC). Hepatogastroenterology 1996;43:1405–1409.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.